Two Unconventional Yet Effective Paths to Differentiation

Posted by Josh Hattem on Fri, Jan 24, 2020

Emily Mandell co-wrote this blog post with Josh Hattem.

With the return on development investment declining in pharma, product differentiation is more important than ever. In our last two blog posts, we explained the challenges surrounding product differentiation and shared four potential paths to clinical differentiation. Here we explore the final two – and most unconventional – paths to differentiation: solving a different problem and building a different yardstick.


>
Read More

What China’s Latest Drug Negotiations Mean for Global Pharma Companies

Posted by Crystal Lam on Wed, Jan 22, 2020

Sonia Yan and Daniel Blessing co-authored this blog post with Crystal Lam.

China’s National Healthcare Security Administration (NHSA) recently released the outcomes of its 2019 National Reimbursed Drug List (NRDL) negotiations: 70 of 119 new therapies were successfully listed. This record outcome more than doubled the number of therapies reimbursed through China’s negotiation pathway, which was formally implemented in 2017.


>
Read More

Going Global With Analytics: Plan Before You Leap

Posted by Pragati Lodha on Mon, Jan 20, 2020

Iain Fratter co-wrote this post with Pragati Lodha 


>
Read More

Bringing the Customer Journey to Life

Posted by Erika Papaccioli. on Thu, Jan 16, 2020

Leslie Happas Norton and Giulia Lopomo co-wrote this blog post with Erika Papaccioli.

Great marketing is about establishing value for the customer and, ultimately, changing behavior. It’s a goal that requires a firm grounding in customer insight, which ultimately fuels memorable, impactful brand campaigns. A good example of this is the recent Chantix campaign featuring celebrity spokesperson Ray Liotta. Born out of the insight that it’s believed to be a sign of weakness to reach out for help quitting smoking, the ads juxtapose “tough guy” Liotta with the need for Chantix—showing smokers that they don’t have to quit on their own.


>
Read More

The Keys to Successful Digital Therapeutics Commercialization

Posted by Pete Masloski on Wed, Jan 08, 2020

One of the more exciting areas in the world of digital health is a subset of solutions known as digital therapeutics, or DTx. The Digital Therapeutics Alliance defines them as “software-based solutions used by patients and their caregivers or providers that are clinically validated where their use leads to a tangible improvement in health outcomes.” Pear Therapeutics, Propeller Health and Voluntis are a few of the pioneering companies that have introduced DTx solutions. Many DTx solutions implement an established behavioral or physical therapy with software tailored to each patient. Others use video games or virtual reality to alleviate pain or address ADHD.


>
Read More